SSKN Strata Skin Sciences

STRATA Skin Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

STRATA Skin Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

HORSHAM, Pa., Oct. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its third quarter 2021 financial results after the market closes on Wednesday, November 10, 2021. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 p.m. Eastern time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

The link to the webcast will be available on the STRATA Skin Sciences website at  under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (855) 327-6837 (US/Canada) or (631) 891-4304 (International) and use the conference ID 10017028.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and now Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The Company’s proprietary XTRAC and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone.

STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact  
Leigh Salvo  
(415) 937-5404  
  



EN
27/10/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes f...

STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in excimer laser therapy for inflammatory and autoimmune dermatologic diseases, today announced that the Centers for ...

 PRESS RELEASE

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on...

STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update HORSHAM, Penn., Nov. 05, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2025 financial results on Thursday, November 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Thur...

 PRESS RELEASE

STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Me...

STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements HORSHAM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies for the treatment of skin conditions such as acne, psoriasis, and vitiligo, today announced that its TheraClearX® acne treatment system has received regulatory clearance from the Mexican health authority, COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), under Device Registration No. 3187E2024SSA, valid through Novem...

 PRESS RELEASE

STRATA Skin Sciences Reinforces Market Leadership Following Key Litiga...

STRATA Skin Sciences Reinforces Market Leadership Following Key Litigation Milestones Against LaserOptek HORSHAM, Penn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today provided an update on its competitive positioning and ongoing litigation against LaserOptek America Corp., LaserOptek Co. Ltd. (“LaserOptek Korea”), and affiliated entities including The Pinnacle Health Group and...

 PRESS RELEASE

Excimer Laser Demonstrates Promising Results in Treating Rare Variant ...

Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to address the condition HORSHAM, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch